Trial Profile

A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs H 1PV (Primary) ; H 1PV (Primary)
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
Acronyms ParvOryx02
Sponsors Oryx GmbH & Co

23 Aug 2021 Results published in the Clinical Cancer Research
30 Oct 2019 According to an Oryx GmbH & Co media release, final results from this trial were presented at the International Oncolytic Virus Conference at the Mayo Clinic Center in Rochester (October 9-12, 2019).
30 Oct 2019 According to an Oryx GmbH & Co media release, Preliminary data from this trial were presented at the Oncolytic Virus Immunotherapy Summit in London (March 20-21, 2019).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com